
    
      Primary Objectives:

      a. To assess whether daily oral Vitamin B12 decreases average joint pain in women with
      aromatase inhibitor-associated musculoskeletal symptoms (AIMSS), as measured at baseline, 6
      weeks and at 12 weeks by the modified Brief Pain Inventory Short Form (BPI-SF).

      Secondary Objectives:

        1. To investigate whether daily vitamin B12 improves functional quality of life as measured
           by the Functional Assessment of Cancer Therapy-Endocrine Scale (FACT-ES);

        2. To explore the impact of treatment on serum inflammatory cytokine levels (C Reactive
           Protein) with 12 weeks of treatment between baseline and 12 weeks.
    
  